Parkinson-Alzheimer-Dementia NGS Panel - The leading Health & Diagnostic provider for DNA, Genetic Tests & Cancer Screening in Dubai, UAE
Parkinson-Alzheimer-Dementia NGS Panel

Parkinson-Alzheimer-Dementia NGS Panel

There are numerous genes associated with dementia, Alzheimer and Parkinson disease. While some of them present particular manifestations that might aid an accurate diagnosis, most of the time, the clinical presentation exhibits common characteristics, making difficult to establish a precise diagnosis.

Category:
  • Description
  • Additional information

Description

There are numerous genes associated with dementia, Alzheimer and Parkinson disease. While some of them present particular manifestations that might aid an accurate diagnosis, most of the time, the clinical presentation exhibits common characteristics, making difficult to establish a precise diagnosis. Evidence shows that the conditions are the result of a combination of genetic and environmental factors. In the general population, the risk to develop any of these conditions is estimated to be at least 10%. This risk at least doubles for people with an affected first-degree relative. The risk can be estimated more precisely when the genetic cause is known, given that some mutations might confer a higher risk, including early onset presentations. Learning about the genetic risk for these conditions might be of utility for making informed decisions related to medical management and care of a patient and to identify who among the direct family members is at higher or at lower risk.

Additional information

Test Code

E3335

Application(s)

Considering the significant overlap between the different types of dementia, Alzheimer and Parkinson, identifying the underlying genetic cause can often help to clarify the diagnosis, guide the development of a personalised medical management plan, and avoid unnecessary or ineffective treatments. Learning about the genetic cause of the condition also allows at-risk family members the option to have genetic testing to determine if they may have the condition and/or if they would benefit from additional medical management.

Techniques

NGS (Full sequencing with del/dup)

Sample Type

Whole Blood

Sample Report

http://www.easternbiotech.com/beta/wp-content/uploads/2017/04/Alzheimer-parkinson-dementia-model-report.pdf

TAT

4-6 weeks